<DOC>
	<DOCNO>NCT00410072</DOCNO>
	<brief_summary>The purpose study compare effectiveness entecavir plus tenofovir combination therapy entecavir monotherapy . Safety also study .</brief_summary>
	<brief_title>Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy Naive Subjects With Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Chronic hepatitis B virus ( HBV ) infection ( hepatitis B e antigen [ HbeAg ] positive negative ) disease Nucleoside nucleotidenaive Males female ≥16 year age ( minimum age consent give country ) Compensated liver function HBV DNA &gt; 1.72*10*5*IU/mL ( approximately 10*6*copies/mL ) HbeAgpositive participant HBV DNA &gt; 1.72*10*4*IU/mL ( approximately 10*5*copies/mL ) HbeAgnegative participant Alanine aminotransferase level ≥*upper limit normal ( ULN ) ≤10*ULN Evidence decompensated cirrhosis Coinfection human immunodeficiency virus , hepatitis C virus , hepatitis D virus Laboratory value protocolspecified range</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>